OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sher on ASTRO's Head and Neck Cancer Guideline Update

March 24th 2016

David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.

Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges

March 24th 2016

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Dr. Thompson on Oncologists Using Social Media

March 23rd 2016

Michael A. Thompson, MD, PhD, oncology/hematology, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses easy steps for oncologists to start using social media.

Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLL

March 22nd 2016

Stephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

March 21st 2016

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.

Dr. Sznol on Immunotherapy in Patients With RCC

March 19th 2016

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

Dr. Crawford on Abiraterone Versus Enzalutamide in Prostate Cancer

March 19th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting abiraterone versus enzalutamide for the treatment of patients with castration-resistant prostate cancer.

Dr. Tap on Olaratumab in Patients With Soft Tissue Sarcoma

March 18th 2016

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

Dr. Krajewski on Responses With PD-1 Agents in RCC

March 17th 2016

Katherine Krajewski, MD, associate director, physician, Cancer Imaging Program Fellowship, Dana-Farber Cancer Institute, assistant professor of Radiology, Harvard Medical School, discusses the range of responses seen in patients with renal cell carcinoma (RCC) who have received PD-1 agents as treatment.

Dr. Chandra Belani on Atezolizumab in NSCLC

March 16th 2016

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

Dr. Peter Martin on Future Treatment Approaches in Mantle Cell Lymphoma

March 15th 2016

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

March 14th 2016

James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

March 14th 2016

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma

March 10th 2016

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Dr. Elias Obeid on Androgen Receptor Expression in Triple-Negative Breast Cancer

March 8th 2016

Elias Obeid, MD, MPH, assistant professor, Department of Clinical Genetics, Fox Chase Cancer Center, discusses a retrospective analysis that investigated androgen receptor expression in patients with triple-negative breast cancer. (TNBC).

Dr. Landman on Delivering Value-Based Care to Patients

March 7th 2016

Zachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.

Dr. Belani on Impact of Nivolumab's Approval in NSCLC

March 4th 2016

Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of nonâ€“small cell lung cancer (NSCLC).

Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

March 3rd 2016

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Dr. Turkbey on Sodium Fluoride PET Imaging for Prostate Cancer

March 3rd 2016

Ismail Baris Turkbey, MD, staff clinician in the Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, discusses sodium fluoride PET imaging for patients with prostate cancer.

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

March 2nd 2016

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.